Kadcyla (ado-trastuzumab emtansine)

Owing to active renal lesions, the patient was treated with prednisolone and cyclophosphamide, which resulted in clinical remission. This case was considered to have T-DM1-associated IgA vasculitis. Although rare, an awareness of the possibility of serious adverse effects associated with drug administration is important.

P2, N=131, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

She received first-line chemotherapy with trastuzumab, pertuzumab, and docetaxel, followed by maintenance anti-HER2 therapy and surgery for local disease control. This case may represent an exceptional response to T-DM1 and highlights the potential for durable complete remission in selected patients with HER2-positive metastatic breast cancer. Further investigation is warranted to identify predictive factors for exceptional responses and to determine optimal treatment duration.

P3, N=608, Completed, Daiichi Sankyo | Active, not recruiting --> Completed

Notably, RC48 retained strong activity in BT474-derived sublines resistant to T-DM1, lapatinib, or neratinib, inducing cell cycle arrest, apoptosis, and caspase activation in all resistant models. Together, these findings identify disitamab vedotin as a potent next-generation HER2-targeting ADC with the unique capacity to overcome acquired resistance to HER2-directed therapies. RC48 represents a promising therapeutic strategy for patients with refractory HER2-positive breast cancer and warrants further clinical investigation.

P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

P2, N=55, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2027 --> Feb 2029 | Trial primary completion date: Feb 2026 --> Feb 2028

P1/2, N=320, Active, not recruiting, Ascendis Pharma Oncology Division A/S | Recruiting --> Active, not recruiting

T-DM1 is a cost-effective and dominant strategy for the adjuvant treatment of residual invasive HER2+ early BC in Colombia, driven by cost savings from reduced high-cost recurrences. These findings support the adoption of T-DM1 to improve outcomes while ensuring efficient use of healthcare resources.

P2, N=186, Active, not recruiting, National Medical Research Radiological Centre of the Ministry of Health of Russia

P2, N=512, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed

MRI-guided optimisation of neoadjuvant chemotherapy duration was associated with favourable 3-year event-free survival outcomes in patients with stage II-III HER2-positive breast cancer. This approach represents a novel strategy that reduces treatment burden, minimises toxicity, and preserves quality of life in a subset of patients with early HER2-positive breast cancer.